Straumann Holding AGXSWX:STMN +1.50%100 EV-to-EBIT is 35.52 as of Jul. 11, 2026, which is 5% below its 10-year median of 37.40. GuruFocus rates XSWX:STMN with a GF Score™ of 100/100 and a GF Value™ of CHF137.43 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 464 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 75.86% on this metric.
The historical rank and industry rank for Straumann Holding AG's EV-to-EBIT or its related term are showing as below:
XSWX:STMN'
s EV-to-EBIT Range Over the Past 10 Years
Min: 23.92 Med: 37.4 Max: 252.76
Current: 35.53
During the past 13 years, the highest EV-to-EBIT of Straumann Holding AG was 252.76. The lowest was 23.92. And the median was 37.40.
XSWX:STMN's EV-to-EBIT is ranked worse than 75.86% of 464
companies
in the Medical Devices & Instruments industry
Industry Median: 18.34
vs XSWX:STMN: 35.53
Straumann Holding AG (XSWX:STMN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Straumann Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF14,836 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF470 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG EV-to-EBIT Related Terms
Straumann Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:STMN vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's EV-to-EBIT falls into.
Straumann Holding AG's current Enterprise Value is CHF16,708 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF470 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (XSWX:STMN) has a EV-to-EBIT of 35.52 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Straumann Holding AG and its competitors. This is near median its historical median of 37.40. Over the past decade, Straumann Holding AG's EV-to-EBIT has ranged from 23.92 to 252.76. According to the industry distribution chart, Straumann Holding AG ranks #352 out of 464 companies in the Medical Devices & Instruments industry, placing it in the top 75.9%.
Is Straumann Holding AG's EV-to-EBIT too high?
Straumann Holding AG's current EV-to-EBIT of 35.52 is near median its 10-year median of 37.40. Over the past 10 years, this metric has ranged from a low of 23.92 to a high of 252.76. The Medical Devices & Instruments industry median EV-to-EBIT is 18.34. Straumann Holding AG's value of 35.52 is 93.7% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #352 out of 464 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Straumann Holding AG has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #352 out of 464 companies for EV-to-EBIT. This places Straumann Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 18.34. Straumann Holding AG's value of 35.52 is 93.7% above this benchmark. Historically, Straumann Holding AG's own EV-to-EBIT has ranged from 23.92 to 252.76 over the past decade. While the company's 10-year median is 37.40 vs. the industry median of 18.34, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.34, based on 464 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current EV-to-EBIT of 35.52 is 93.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current EV-to-EBIT is 35.52, which is near median its own 10-year median of 37.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.43, compared to a current price of CHF105.20 — trading 23.5% below its estimated fair value. The current EV-to-EBIT is 35.52, which is near median its 10-year median of 37.40 and 93.7% above the Medical Devices & Instruments industry median of 18.34. Straumann Holding AG's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current EV-to-EBIT is 35.52 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF105.20 is trading 23.5% below its estimated GF Value™ of CHF137.43.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
EV-to-EBIT: 35.52 (near median its 10-year median of 37.40)
GF Value™: CHF137.43 vs. price of CHF105.20 (23.5% below fair value)
Industry Position: 93.7% above the Medical Devices & Instruments median (#352 of 464)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
100GF Score
Get the complete analysis for XSWX:STMN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
